Literature DB >> 23497939

Sjögren's syndrome and the epithelial target: a comprehensive review.

M J Barrera1, V Bahamondes, D Sepúlveda, A F G Quest, I Castro, J Cortés, S Aguilera, U Urzúa, C Molina, P Pérez, P Ewert, C Alliende, M A Hermoso, S González, C Leyton, M J González.   

Abstract

The most difficult component in our understanding of human autoimmunity remains a rigorous dissection of etiological events. Indeed, the vast literature on autoimmune diseases focuses on the inflammatory response, with the hope of developing drugs that reduce inflammation. However, there is increasing recognition that understanding the immunobiology of target tissues will also have direct relevance to disease natural history, including breach of tolerance. Sjögren's syndrome is essentially an epitheliitis and there are major changes to normal architectural salivary organization. We propose that loss of homeostasis is the initial event that precipitates inflammation and that such inflammatory response includes not only the adaptive response, but also an intense innate immune/bystander response. To understand these events this review focuses on the architecture, phenotype, function and epithelial cell organization. We further submit that there are several critical issues that must be defined to fully understand epithelial cell immunobiology in Sjögren's syndrome, including defining epithelial cell polarity, cell-cell and cell to extracellular matrix interactions and a variety of chemical and mechanical signals. We also argue that disruption of tight junctions induces disorganization of the apical pole of salivary acinar cells in Sjögren's syndrome. In addition, there will be a critical role of inflammatory cytokines in the apico-basal relocation of tight junction proteins. Further, the altered disorganization and relocation of proteins that participate in secretory granule formation are also dysregulated in Sjögren's syndrome and will contribute to abnormalities of mucins within the extracellular matrix. Our ability to understand Sjögren's syndrome and develop viable therapeutic options will depend on defining these events of epithelial cell biology.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23497939     DOI: 10.1016/j.jaut.2013.02.001

Source DB:  PubMed          Journal:  J Autoimmun        ISSN: 0896-8411            Impact factor:   7.094


  30 in total

1.  The challenge of treating orphan disease.

Authors:  Carlos Dias; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-12       Impact factor: 8.667

2.  Restoration of CFTR Activity in Ducts Rescues Acinar Cell Function and Reduces Inflammation in Pancreatic and Salivary Glands of Mice.

Authors:  Mei Zeng; Mitchell Szymczak; Malini Ahuja; Changyu Zheng; Hongen Yin; William Swaim; John A Chiorini; Robert J Bridges; Shmuel Muallem
Journal:  Gastroenterology       Date:  2017-06-19       Impact factor: 22.682

3.  Roles of claudin-5 and von Willebrand factor in patients with rheumatoid arthritis.

Authors:  Gönül Gurol; Ihsan Hakkı Ciftci; Halil Harman; Engin Karakece; Ayhan Kamanli; Ibrahim Tekeoglu
Journal:  Int J Clin Exp Pathol       Date:  2015-02-01

Review 4.  Cutaneous and Mucosal Manifestations of Sjögren's Syndrome.

Authors:  Elena Generali; Antonio Costanzo; Carlo Mainetti; Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2017-12       Impact factor: 8.667

5.  P2X7 receptor antagonism prevents IL-1β release from salivary epithelial cells and reduces inflammation in a mouse model of autoimmune exocrinopathy.

Authors:  Mahmoud G Khalafalla; Lucas T Woods; Jean M Camden; Aslam A Khan; Kirsten H Limesand; Michael J Petris; Laurie Erb; Gary A Weisman
Journal:  J Biol Chem       Date:  2017-08-10       Impact factor: 5.157

Review 6.  Autoimmunity in 2013.

Authors:  Carlo Selmi
Journal:  Clin Rev Allergy Immunol       Date:  2014-08       Impact factor: 8.667

7.  Mastitis associated with Sjögren's syndrome: a series of nine cases.

Authors:  Radjiv Goulabchand; Assia Hafidi; Ingrid Millet; Jacques Morel; Cédric Lukas; Sébastien Humbert; Sophie Rivière; Christian Gény; Christian Jorgensen; Alain Le Quellec; Hélène Perrochia; Philippe Guilpain
Journal:  Immunol Res       Date:  2017-02       Impact factor: 2.829

8.  Serum CXCL4 increase in primary Sjögren's syndrome characterizes patients with microvascular involvement and reduced salivary gland infiltration and lymph node involvement.

Authors:  Serena Vettori; Rosaria Irace; Antonella Riccardi; Daniela Iacono; Luciana Pellecchia; Lucia Vicedomini; Gabriele Valentini
Journal:  Clin Rheumatol       Date:  2016-08-26       Impact factor: 2.980

Review 9.  Childhood Sjögren syndrome: insights from adults and animal models.

Authors:  Scott M Lieberman
Journal:  Curr Opin Rheumatol       Date:  2013-09       Impact factor: 5.006

10.  Monocytes from Sjögren's syndrome patients display increased vasoactive intestinal peptide receptor 2 expression and impaired apoptotic cell phagocytosis.

Authors:  V Hauk; L Fraccaroli; E Grasso; A Eimon; R Ramhorst; O Hubscher; C Pérez Leirós
Journal:  Clin Exp Immunol       Date:  2014-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.